Search results
Results from the WOW.Com Content Network
Argentina confirmed the presence of the Mu variant in the country with one case reported. The patient is a 33-year-old woman who previously had two doses of the COVID-19 vaccine. The patient resides in the San Martín department, in the north of the province of Salta. The patient presented mild symptoms and did not require hospitalization. [32]
The updated vaccines from Pfizer and Moderna for people ages 6 months and older come amid a summer surge in COVID-19 cases across the U.S. Walgreens and CVS, two of the largest chains, previously ...
The US Food and Drug Administration announced Friday that it had advised the makers of the Covid-19 vaccines to formulate their new shots to be a better match for the JN.1 lineage of the coronavirus.
The FDA is reversing course on its COVID vaccine guidance: Rather than having a vaccine that targets the older JN.1 variant, the FDA said fall 2024 vaccines should target a newer strain of the virus.
The potential emergence of a SARS-CoV-2 variant that is moderately or fully resistant to the antibody response elicited by the COVID-19 vaccines may necessitate modification of the vaccines. [336] The emergence of vaccine-resistant variants is more likely in a highly vaccinated population with uncontrolled transmission.
BA.2.86 was first reported by Denmark and Israel. [1] [11] On 18 August 2023, when only six cases had been reported from four countries (Denmark, Israel, the United Kingdom and the United States), the British healthcare authorities noted that its almost simultaneous appearance in several countries still operating detailed genomic surveillance indicated that it likely already was spreading more ...
Earlier this month, the health regulator approved updated COVID-19 vaccines made by Pfizer and Moderna targeting the KP.2 variant. JN.1 was the dominant strain in the United States earlier this year.
In June 2023, the FDA advised manufacturers that the 2023–2024 formulation of the COVID‑19 vaccines for use in the US be updated to be a monovalent COVID‑19 vaccine using the XBB.1.5 lineage of the Omicron variant.